Raymond James & Associates Immuno Gen, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$12.46 - $29.95 $786,138 - $1.89 Million	-63,093 Reduced 37.65%	104,485 $3.1 Million
Q3 2023 Oct 24, 2023	BUY	$14.09 - $19.87 $2.12 Million - $2.99 Million	150,652 Added 890.06%	167,578 $2.66 Million
Q2 2023 Jul 25, 2023	SELL	$3.75 - $20.05 $106,807 - $571,064	-28,482 Reduced 62.72%	16,926 $319,000
Q1 2023 Apr 14, 2023	BUY	$3.67 - $4.92 $20,764 - $27,837	5,658 Added 14.23%	45,408 $174,000
Q4 2022 Feb 08, 2023	SELL	$4.55 - $6.31 $777,990 - $1.08 Million	-170,987 Reduced 81.14%	39,750 $197,000
Q3 2022 Oct 25, 2022	SELL	$4.48 - $6.47 $90,213 - $130,286	-20,137 Reduced 8.72%	210,737 $1.01 Million
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $34,857 - $63,740	-11,066 Reduced 4.57%	230,874 $1.04 Million
Q1 2022 May 11, 2022	SELL	$4.26 - $7.48 $50,830 - $89,251	-11,932 Reduced 4.7%	241,940 $1.15 Million
Q4 2021 Feb 08, 2022	SELL	$4.75 - $7.5 $25,626 - $40,462	-5,395 Reduced 2.08%	253,872 $1.88 Million
Q3 2021 Nov 02, 2021	SELL	$5.02 - $6.59 $17,926 - $23,532	-3,571 Reduced 1.36%	259,267 $1.47 Million
Q2 2021 Aug 11, 2021	SELL	$5.79 - $8.6 $34,456 - $51,178	-5,951 Reduced 2.21%	262,838 $1.73 Million
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $14,423 - $23,366	-2,219 Reduced 0.82%	268,789 $2.18 Million
Q4 2020 Feb 12, 2021	SELL	$3.7 - $7.66 $71,961 - $148,979	-19,449 Reduced 6.7%	271,008 $1.75 Million
Q3 2020 Nov 04, 2020	SELL	$3.45 - $4.89 $78,832 - $111,736	-22,850 Reduced 7.29%	290,457 $1.05 Million
Q2 2020 Jul 28, 2020	BUY	$3.32 - $5.34 $53,388 - $85,872	16,081 Added 5.41%	313,307 $1.44 Million
Q1 2020 Apr 21, 2020	SELL	$2.12 - $6.8 $502,149 - $1.61 Million	-236,863 Reduced 44.35%	297,226 $1.01 Million
Q4 2019 Feb 12, 2020	SELL	$2.25 - $5.8 $111,028 - $286,206	-49,346 Reduced 8.46%	534,089 $2.73 Million
Q3 2019 Nov 07, 2019	SELL	$2.22 - $3.39 $23,512 - $35,903	-10,591 Reduced 1.78%	583,435 $1.41 Million
Q2 2019 Aug 06, 2019	SELL	$1.8 - $3.3 $45,534 - $83,480	-25,297 Reduced 4.08%	594,026 $1.29 Million
Q1 2019 May 06, 2019	BUY	$2.41 - $5.91 $57,295 - $140,504	23,774 Added 3.99%	619,323 $1.68 Million
Q4 2018 Feb 11, 2019	SELL	$3.94 - $9.7 $209,938 - $516,854	-53,284 Reduced 8.21%	595,549 $2.86 Million
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $645 - $844	75 Added 0.01%	648,833 $6.14 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $223,329 - $285,026	23,459 Added 3.75%	648,758 $6.31 Million
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $39,811 - $76,948	5,942 Added 0.96%	625,299 $6.58 Million
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $819,327 - $1.28 Million	161,603 Added 35.3%	619,357 $3.97 Million
Q3 2017 Nov 13, 2017	SELL	$5.4 - $8.47 $486,880 - $763,680	-90,163 Reduced 16.46%	457,754 $3.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	547,917	547,917 $3.9 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account